Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage
Source: View publication →
The INTERACT2 trial found that early intensive blood pressure lowering (systolic target <140 mmHg) did not significantly reduce the primary composite outcome of death or major disability at 90 days compared to guideline-based management (systolic target <180 mmHg), although a secondary ordinal analysis suggested a potential benefit in functional recovery.
Key Findings
Study Design
Study Limitations
Clinical Significance
While the primary result did not achieve formal statistical significance, the favorable ordinal shift in disability and the demonstrated safety of the protocol suggest that early intensive blood pressure management (target <140 mmHg) is a reasonable and safe strategy for patients presenting with acute spontaneous intracerebral hemorrhage, influencing subsequent clinical practice and guidelines.
Historical Context
Following the pilot INTERACT1 trial, which showed the feasibility of rapid blood pressure reduction and its association with reduced hematoma expansion, INTERACT2 was designed as a definitive Phase 3 trial to assess whether this approach improved long-term clinical outcomes in patients with spontaneous intracerebral hemorrhage.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale for lowering blood pressure acutely in spontaneous intracerebral hemorrhage (ICH), and how does this differ from the management of acute ischemic stroke?
Key Response
The primary goal in ICH is to reduce the hydrostatic pressure exerted on the ruptured vessel to prevent 'hematoma expansion,' which occurs in up to 30% of patients and is a major predictor of poor outcome. In contrast, in acute ischemic stroke (unless thrombolysis is planned), the blood pressure is often allowed to remain higher (permissive hypertension) to maintain collateral flow to the ischemic penumbra.
Based on the INTERACT2 results, if you achieve a systolic blood pressure (SBP) of 135 mmHg in a patient within 6 hours of ICH onset, what are the expected clinical benefits and the potential safety concerns compared to a standard target of <180 mmHg?
Key Response
INTERACT2 suggests that intensive lowering (<140 mmHg) is safe and may improve functional recovery (as shown in the shift analysis of the modified Rankin Scale). Unlike the later ATACH-II trial, INTERACT2 did not show a significant increase in renal adverse events, though it also failed to show a significant reduction in the primary outcome of death or major disability (mRS 3-6).
INTERACT2 reported a p-value of 0.06 for its primary dichotomous outcome (death or major disability) but a p-value of 0.04 for the secondary ordinal analysis (mRS shift). How should a subspecialist interpret these conflicting signals regarding the efficacy of intensive BP lowering?
Key Response
The discrepancy highlights the loss of statistical power when dichotomizing continuous functional scales. The shift analysis suggests a consistent 'slide' toward better outcomes across all levels of disability, which may be more clinically representative than an arbitrary cutoff at mRS 3. However, since the primary endpoint was not met, the results must be viewed as hypothesis-generating or supportive rather than definitive evidence of superiority.
When reconciling the INTERACT2 findings with the ATACH-II trial results, how do you determine the 'ideal' blood pressure target for a patient with ICH in the first 24 hours of admission?
Key Response
The 'sweet spot' appears to be achieving a target of 140 mmHg without aggressive overshooting. ATACH-II used more intensive intravenous nicardipine to reach targets faster and showed higher rates of renal injury without benefit. INTERACT2 achieved targets more gradually. Practically, this suggests aiming for 140 mmHg is beneficial, but the speed and intensity of pharmacotherapy should be balanced to avoid acute kidney injury and extreme hypotension (<120 mmHg).
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The INTERACT2 trial utilized an ordinal analysis (proportional-odds model) for the modified Rankin Scale as a secondary endpoint. What are the statistical assumptions required for this model to be valid, and why might this approach be more sensitive than a binary logistic regression in stroke trials?
Key Response
The proportional-odds assumption requires that the treatment effect (odds ratio) is the same across all possible cut-points of the mRS. Ordinal analysis is more sensitive because it utilizes the full distribution of the data, capturing improvements such as a move from mRS 5 to 4, which a binary '0-2 vs 3-6' analysis would count as a failure, thereby increasing the effective power of the study.
INTERACT2 was an open-label trial where the primary outcome (mRS at 90 days) was assessed by observers who were aware of the treatment allocation in some cases. As a reviewer, how would you weigh the threat of 'expectation bias' against the 'near-significant' primary p-value of 0.06?
Key Response
In an open-label design, even with blinded adjudicators, the lack of a placebo control for BP management can lead to subtle differences in nursing care or rehabilitation efforts. A p=0.06 is particularly vulnerable to this bias, as even a small number of misclassified mRS scores due to observer enthusiasm for the intensive arm could shift the result from non-significant to significant, demanding a conservative interpretation.
Current AHA/ASA guidelines (2022) provide a Class 2a recommendation for acute BP lowering to 140 mmHg in patients presenting with SBP between 150-220 mmHg. Why does INTERACT2's lack of success on its primary endpoint prevent this from being a Class 1 recommendation?
Key Response
A Class 1 (Level A) recommendation typically requires multiple large RCTs with significant results on the primary endpoint. Because INTERACT2's primary endpoint was p=0.06 and the subsequent ATACH-II trial was stopped for futility (showing no benefit and potential renal harm), the evidence remains 'moderate' (Class 2a), indicating that while the intervention is reasonable and likely beneficial, the evidence base lacks the definitive strength for a mandatory standard of care.
Clinical Landscape
Noteworthy Related Trials
ENIGMA Trial
Tested
Early intensive blood pressure lowering (target SBP <140 mmHg)
Population
Patients with acute intracerebral hemorrhage
Comparator
Standard care (target SBP <180 mmHg)
Endpoint
Hematoma growth at 24 hours
INTERACT2 Trial
Tested
Intensive blood pressure lowering (target SBP <140 mmHg within 1 hour)
Population
Patients with acute spontaneous intracerebral hemorrhage within 6 hours of onset
Comparator
Guideline-based blood pressure lowering (target SBP <180 mmHg)
Endpoint
Death or major disability at 90 days (modified Rankin scale scores 3–6)
ATACH-2 Trial
Tested
Intensive blood pressure lowering (target SBP 110-139 mmHg)
Population
Patients with acute intracerebral hemorrhage within 4.5 hours of onset
Comparator
Standard blood pressure lowering (target SBP 140-179 mmHg)
Endpoint
Death or disability at 3 months (modified Rankin scale scores 4–6)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis